natgillin/translations-raw huggingface dataset:
A compound for use according to claim 9 wherein the endoparasitic infection is caused by a helminth selected from the group consisting of Anaplocephala, Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorous, Uncinaria, Wuchereria, and combinations thereof. 
HR P20190408 T1 se prenose helmintima odabranima iz skupine koja se sastoji od sljedećih: Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorus, Uncinaria, Wuchereria i njihove kombinacije.
providing a second support system positioned adjacent to the second guide remote from the door for supporting a second portion of the object; and while the object is supported by the second support system, allowing the object to move relative to the second guide until the second portion of the object contacts the second guide. 
drugi pokretni sustav (718) smješten susjedno drugoj vodilici i dalje od vrata radi podupiranja drugog kotača; i omogućavanje drugom pokretnom sustavu (718) da klizi u prvom smjeru i prenosi vozilo u prvom smjeru sve dok drugi kotač ne dođe u doticaj s drugom vodilicom (804).
The invention provides an isolated or recombinant fusion protein dimer comprising two monomeric fusion proteins linked via at least one disulfide bond formed between two cysteine residues present in each monomeric mutant fusion protein, wherein each monomeric fusion protein comprises (a) a polypeptide comprising a polypeptide sequence which differs from SEQ ID NO:50 in no more than 6 amino acid residues and which includes residues at positions 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 and 106 that are identical to the amino acid residues at the corresponding positions in SEQ ID NO:50 and (b) an Ig Fc polypeptide, and wherein the fusion protein dimer binds human CD80 or human CD86 or an extracellular domain of either and has a greater ability to suppress an immune response than a LEA29Y-Ig fusion protein dimer, wherein the LEA29Y-Ig fusion protein dimer comprises two monomeric LEA29Y-Ig fusion proteins each comprising the polypeptide sequence of SEQ ID NO:166. 
HR P20130194 T1 PATENTNI ZAHTJEVI Izolirani ili rekombinantni polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka 1 koja uključuje ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 1 106 koji su identični sa aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36, naznačen time da polipeptid veže humani CD80 ili humani CD86 ili izvanstaničnu domenu bilo kojeg od njih i ima sposobnost inhibicije imunološkog odgovora koja je veća od sposobnosti inhibicije imunološkog odgovora polipeptida LEA29Y koji sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
V is hydrogen, straight- or branched-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO2, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; substituted or unsubstituted cycloalkyl; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. 
V je vodik, ravni- ili razgranati-, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani alkenil, supstituirani ili nesupstituirani alkinil, gdjejedan ili više metilena mogu biti prekinuti ili završeni sa O, S, S(O), SO2, N(R8), C(O), supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani heteroaril, supstituirani ili nesupstituirani heterocikal; supstituirani ili nesupstituirani cikloalkil; pri čemu R8 je vodik, acil, alifatski ili alifatski supstituirani.
A substantial advantage of the method according to this invention over the prior art ones is that in the oxidation of 7-ethyl-1,2,6,7-tetrahydrocamptothecin no coloured side products are formed that need be removed by chromatography on a silica gel column. 
Znatna prednost postupka prema ovom izumu u odnosu na one ranije je da kod oksidacije 7-etil-1,2,6,7-tetrahidrokamptotecina nema obojenih nusprodukata, koje bi trebalo ukloniti kromatografijom na stupcu silikagela.
The pharmaceutical formulation for use according to any one of claims 4-12, wherein the pharmaceutical formulation comprises a mixture of the therapeutically effective amount of diazoxide choline or polymorph B of diazoxide choline and the melanocortin-4-receptor agonist. 
liječenje subjekta koji boluje od ili je u opasnosti da oboli od Alzheimerove bolesti, što se sastoji u primjeni na navedenom subjektu terapijski djelotvorne količine navedene formulacije;
The meglumine salt or a hydrate thereof according to claim 1, wherein the meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or the hydrate thereof is a crystal. 
Megluminska sol ili hidrat istog u skladu s patentnim zahtjevom 1, naznačena time, daje megluminska sol 6-fluoro-3-hidroski-2-pirazinkarboksamida ili hidrat istog kristal.
is selected from the group consisting of phenyl(C1-3)alkyl, pyridinyl(C1-3)alkyl, and furanyl(C1-3)alkyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-3alkoxy; tetrazolyl, C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein G6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; chloro; fluoro; trifluoromethoxy; and carboxy; 
R! je izabran iz skupine koju čine fenil(C;.g)alkil, piridiniKC,.s)alkil i furani(C,.3)alkil; pri čemu fenil, piridinil i furanil su proizvoljno supstituirani sa jednim do tri R' supstituenta nezavisno izabrana iz skupine koju čine je C1salkoksi; tetrazolil, Cs.gcikloalkilaminokarbonil; hidroksi(C1.4)alkilaminokarbonil; C4_,oarilaminokarbonil pri čemu Cs.qaril je proizvoljno supstituiran sa karboksi ili C,galkoksikarbonil; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi, metoksikarbonil; i karboksi; uz uvjet da ne više od jedan R!! je Csroarilaminokarbonil,;
The compound according to clause 1, wherein the compound has formula formula I-A wherein, independently for each occurrence: 
Spoj prema patentnom zahtjevu 1, pri čemu je spoj formule I-A ON o-x LI a o O
A preferred, non-limiting embodiment of the invention will be described by way of example with reference to the accompanying drawings, in which: 
Pogodna, neograničavajuća izvedba izuma opisat će se pomoću primjera pozivajući se na pridružene crteže, u kojima: Slika 1
The liquefied gas treatment system according to claim 3, wherein the sub LNG supply line includes a gas-liquid separator configured to separate a heavy hydrocarbon component from the LNG so as to adjust a methane number of the fuel to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (1.24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
The organic phases were combined, washed with brine (50 mL), dried (MgSO4) then the solvent evaporated under reduced pressure. 
Organske faze se pomiješa, ispere slanom vodom (50 ml), osuši (MgSO;), a zatim se otapalo otpari pod sniženim tlakom.
Prodrug esters may also include, but are not limited to, groups such as phosphate esters, phosphonate esters, phosphonamidate esters, sulfate esters, sulfonate esters, and sulfonamidate esters wherein the ester may be further substituted with groups that confer a pharmaceutical advantage such as—but not limited to—favorable aqueous solubility or in vivo exposure to the bioactive component formula I. 
Esteri prolijekova mogu također uključivati, ali bez ograničenje, skupine kao što su fosfatni esteri, fosfonatni esteri, fosfonamidat esteri, sulfatni esteri, sulfonatni esteri i sulfonamidat esteri gdje ester može biti dalje supstituiran sa skupinama koje mogu dati farmaceutsku prednost kao što je, ali nije ograničeno, poželjna topivost u vodi ili in vivo izloženost bioaktivnoj komponenti formule I.
A pharmaceutical composition, comprising an aqueous solution of levofloxacin or ofloxacin and a divalent or trivalent cation, wherein the solution is suitable for inhalation into a lung. 
Postupak maskiranja okusa fluorokinolona izabranog iz levofloksacina ili ofloksacina, obuhvaća spravljanje kompleksa fluorokinolona s dvovalentnim ili trovalentnim kationom.
Again, other designs for the capsule are possible as long as the capsule can be sealed and contain the mentioned ingredients. 
Nadalje, moguće su i druge izvedbe za čahure, dok god čahura može biti nepropusno zatvorena i dok može sadržavati navedene sastojke.
Q is a bond or a C1-C10-alkylene group optionally substituted by halogen; 
Q je veza ili Ci-Ci9-alkilenska skupina prema potrebi supstituirana s halogenim;
In some embodiments, the hemihydrate has a dynamic vapor sorption profile substantially as shown in FIG. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da ima profil dinamičke sorpcije para sadržajno isti kao prikazan na Slici 12.
A compound selected from: 
izabran iz struktura:
wherein Hal represents fluoro or chloro, and R1 and R2 represent, independently from one another, hydrogen or have one of the meanings of Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in a polar non-nucleophilic solvent at a temperature of minus 10° C. to 50° C. and in the presence of a suitable crown ether, to give the compound of formula (I). 
R! i R", međusobno neovisno, predstavljaju vodik ili jedno od značenja Hal; naznačen time što u navedenom postupku spoj formule (II) se prevodi u odgovarajući ester alkil-, fluoralkil- ili arilsulfonske kiseline, koji zatim reagira s nitritom alkalnog metala, u prisutnosti pogodnog krunastog etera, u polarnom nenukleofilnom otapalu, na temperaturi od -10 *C do 50 "€, kako bi se dobilo spoj formule (D).
A method of preparing biscuits or crackers, said method comprising (i) preparing a dough by combining flour, water, leavening agent, a fat blend and optionally further bakery ingredients; and (ii) baking the dough; wherein the fat blend contains at least 30 wt.% of polyunsaturated fatty acids and comprises: 
Postupak priprave biskvita ili keksa, gdje se navedeni postupak sastoji u (1) pripravi dizanog tijesta miješanjem brašna, vode, sredstva za dizanje tijesta, smjese masti i izborno dodatnih sastojaka za peciva; i (ii) pečenju dizanog tijesta; gdje smjesa masti sadrži najmanje 30 %, težinski, višestruko nezasićenih masnih kiselina i sastoji se od:
whereby said amyloid fibrils and said activated carbon are in intimate contact. 
gdje su navedena amiloidna vlakna i navedeni aktivni ugljen u intimnom kontaktu.
0142146 A2, and quinoline and pyridine derivatives, as disclosed in U.S. Patent No. 
0142146 A2, i derivati hinolina i piridina, kao što je navedeno u U.S. Patentu br.
identifying a given area in which electrical energy consumption is to be controlled, the given area being an area of said geographical area supplied by the electricity distribution network; and selecting, based on said location indicators, a plurality of said groups of said electric devices located within said geographical area. 
identifikacije (800) odabranog područja u kojem se treba kontrolirati potrošnja električne energije, a odabrano područje je područje navedenog geografskog područja koje se opskrbljuje iz mreže za distribuciju električne energije; te odabira, na temelju navedenih pokazatelja lokacije, mnoštva navedenih skupina navedenih električnih uređaja (208) koji se nalaze unutar navedenog geografskog područja.
A dosage form according to claim 1, which additionally comprises at least one of the following components a)-f): 
Oblik davanja lijeka prema jednom od patentnih zahtjeva 1 do 9, naznačen time, da sadrži još najmanje jednu od slijedećih komponenata (a) - (£):
The pharmaceutical composition for use according to any one of the claims 1-3 or the package for use according to claim 4, wherein the form of multiple sclerosis is relapsing-remitting multiple sclerosis. 
Farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, ili pakiranje za uporabu u skladu s patentnim zahtjevom 4, naznačeni time, da oblik multiple skleroze jest relapsno-remitirajuća multipla skleroza.
FCS = a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino acid end and a carboxyl end, wherein the FCS: 
FCS = cijepanje sekvencije aminokiselinskih ostataka furinom, koju je sekvenciju moguće cijepati furinom i koja ima na jednom kraju aminokiselinu a na jednom kraju karboksil, pri čemu je taj FCS:
Turbo-generator device according to claim 2, characterised in that said turbo-generator device is reversible for recharging and extracting fluid from aquifers, such that gas can be introduced or extracted from regulating the operating means. 
Turbogeneratorski uređaj prema patentnom zahtjevu 2, naznačen time da je spomenuti turbogeneratorski uređaj Teverzibilan za ponovno punjenje i izvlačenje tekućine iz vodonosnika, na takav način da se plin može ubacivati ili izvlačiti reguliranjem upravljačkih uređaja.
integrating an env gene in such cells using an expression vector culturing the cells to obtain a cell line stably expressing gag, pol, rev, tat and env protein 
Vili. integraciju env gena u takvim stanicama koristeći ekspresijski vektor ix. uzgoj stanica za dobivanje stamene linije stabilno izražavajući gag, pol, rev i env proteine
A cytotoxic compound comprising a linking group with a reactive group bonded thereto capable of covalently linking the cytotoxic compound to a cell binding agent (CBA), wherein said cytotoxic compound is represented by any one of the following formulas: or a pharmaceutically acceptable salt thereof, wherein: 
, ili njihovom farmaceutski prihvatljivom soli, pri čemu je modificirani citotoksični spoj proizveden reagiranjem citotoksičnog spoja koji sadrži imin koji nosi tiol skupinu s imin reaktivnim reagensom i pri čemu je citotoksični spoj koji sadrži imin predstavljen jednom od sljedećih formula:
A method according to any of the claims 1 to 8, wherein the provision of a fiber cement product comprising at least one profiled surface comprises the provision of a green fiber cement plate using a Hatschek process, and profiling at least one surface of said fiber cement plate. A method according to claim 9, wherein the green fiber cement plate is cured using autoclave curing. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što osiguravanje vlaknastog cementnog proizvoda koji sadrži najmanje jednu profiliranu površinu obuhvaća osiguravanje ploče od zelenog vlaknastog cementa uporabom Hatschekovog postupka, i profiliranje najmanje jedne površine navedene ploče od vlaknastog cementa nakon stvrdnjavanja zelene ploče od vlaknastog cementa.
2 Rupture Use of a hydroxypropyl cellulose for coating a tablet, the hydroxypropyl cellulose having a content of hydroxypropyl groups within a range of 42 to 48% by mass. 
PATENTNI ZAHTJEVI 1. - Uporaba hidroksipropilceluloze, naznačena time, da je za oblaganje tablete, pri čemu hidroksipropilceluloza ima sadržaj hidroksipropil-skupina u rasponu od 42 do 48 masenih postotaka.
The combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated. 
Spojeni organski ekstrakti se isperu s fiziološkom, osuše preko MgSO,, filtriraju i upare.
The apparatus according to claim 1, wherein the movement restriction device, the volume filling device or the combined device has a varying circumference so as to be better adapted to be kept invaginated in the stomach wall of the patient, wherein the varying circumference of the combined device comprises at least one of the following shapes: 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uređaj dodatno ima najmanje jedno od sljedećeg: unutarnji izvor napajanja (70; 470), bežični prijemnik energije (205) za neinvazivno napajanje uređaja bežičnom energijom i prijemnik energije koji prima bežičnu energiju radi punjenja unutarnjeg izvora napajanja.
R2: a group represented by the formula (IV) or (V), 
: skupina predstavljena formulom (IV) ili (V): [image]
A synergistic herbicidal mixture as claimed in claim 1 in which the sulfonyl urea is selected from the group consisting of nicosulfuron, tritosulfuron, mesosulfuron, cyclosulfamuron, rimsulfuron, foramsulfuron including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
imazamoks kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom; i metazaklor i kvinmerak uključujući njihove odgovarajuće izomere, kao i njihove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom.
or a heterocyclyl group substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group, and Y is —CH2—. 
(2) heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, Ci. alkilnom skupinom, halogen-Ci.s alkilnom skupinom, C1.g alkoksi skupinom ili halogen-C1.4 alkoksi skupinom; i
The method according to claim 7, wherein switching of the load current is carried out by a changeover switch and a switching element 
prebacivanje struje opterećenja (IL) vrši se pomoću sklopke za prebacivanje (2) i prekidačkog elementa (11); i
followed by mixing, while stirring, in predetermined amounts, the previously obtained polymers, whereby the resulting curable binder is an aqueous solution. 
[d) te se nastavlja sastavljanje, uz miješanje, u predodređenim količinama, prethodno dobivenih polimera, pri čemu je kao rezultat, dobiveno učvršćujuće vezivo, vodena otopina.
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof. 
HO ili njegov stereoizomer, tautomer, farmaceutski prihvatljiva sol, polimorf, ili solvat.
from 15 to 60% by weight, preferably from 20 to 50% by weight, of at least one cement binder; 
Portland vezivo cementa je od 20 do 50% po masi;
The TCR of claim 1, wherein the alpha chain variable domain comprises Q1 to H112 of SEQ ID No: 11, SEQ ID No 12 or SEQ ID No 13 or SEQ ID No 14 or SEQ ID No 15 and/or the beta chain variable domain comprises D1 to T112 of SEQ ID No: 3. The TCR of claim 1, wherein the alpha chain variable domain comprises amino acid resides 1-112 of SEQ ID No: 2, and the beta chain variable domain comprises amino acid residues 1-112 of SEQ ID No: 3. 
T–stanični receptor (TCR) koji ne postoji u prirodi i/ili je pročišćen i/ili konstruiran, koji ima svojstvo vezivanja za FMNKFIYEI (SEQ ID Br: 1) HLA-A2 kompleks i sadrži bar jednu varijabilnu domenu alfa lanca TCR i bar jednu varijabilnu domenu beta lanca TCR, pri čemu varijabilnu domenu alfa lanca sadrži Q1 do H112 iz SEQ ID Br: 11, SEQ ID Br 12, SEQ ID Br 13, SEQ ID Br 14 ili SEQ ID Br 15, i varijabilna domena beta lanca sadrži D1 do T112 iz SEQ ID Br: 3.
a second collar 35 in frictional and slideable engagement with the first collar 32; 
- - drugi prsten 35 u frikcijskom i kliznom spoju s prvim prstenom 32;
deprotecting Compound X to obtain Compound VII or converting Compound X directly to Compound I, wherein Compound IX and X are as follows: 
- < uklanjanje zaštite Spoja X radi dobivanja Spoja VII ili pretvorba Spoja X izravno u Spoj I, gdje su Spoj IX 1 X kako slijedi:
and R2 are bonded to form a 5- or 6-membered ring optionally substituted by alkyl; is 
R' i R* su povezani za tvorbu 5-članog ili 6-članog prstena koji je prema potrebi supstituiran s alkilom;
The antibody for use according to claim 17, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, colorectal cancer, endometrial adenocarcinoma, leukemia, lymphoma, melanoma, esophageal squamous cell cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer and ovarian cancer. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 17, naznačeno time što se rak bira iz skupine koju čine rak dojke, rak prostate, kolorektalni rak, adenokarcinom endometrija, leukemija, limfom, melanom, rak pločastih stanica jednjaka, rak želuca, astrocitni rak, rak endometrija, rak vrata maternice, rak mokraćnog mjehura, rak bubrega, rak pluća i rak jajnika.
Z-sALP-Y-spacer-X-Wn-V, wherein sALP is the extracellular domain of the alkaline phosphatase; wherein V is absent or is an amino acid sequence of at least one amino acid; 
Z-SsALP- Y-razmak-X-Wn-V, naznačena time da sALP je izvanstanična domena alkalne fosfataze; pri čemu V je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
In still another embodiment, the invention provides an isolated monoclonal antibody, or an antigen-binding portion thereof, wherein the antibody specifically binds to IP-10 and comprises: 
Izolirano humano monoklonsko antitijelo, ili njegov antigen-vežući dio, naznačeno time što se antitijelo specifično veže za humani IP-10 i ne reagira unakrsno sa humanim MIG 1 ne reagira unakrsno sa humanim ITAC.
The container according to claim 12, wherein the respective recesses (13) are located at a same height in each of the upright walls (3). 
. Spremnik u skladu s patentnim zahtjevom 13, naznačen time što otvori (15) se nalaze na istoj visini na svakoj stijenci.
a non-unitary formulation) comprising the acid addition salt and the one or more other therapeutic agent together with instructions for combination therapy with the two or more compounds/agents; or • material comprising at least one of the the acid addition salt and the one or more other therapeutic agent together with instructions for administration to a patient population in which the other(s) of the acid addition salt and the one or more other therapeutic agent have been (or are being) administered; or 
nejedinstveni pripravak) koji sadrži laktatnu sol i jedan ili više terapeutskih sredstava zajedno s uputama za kombiniranu terapiju s dva ili više spojeva/sredstava; ili e - materijal koji sadrži najmanje jednu laktatnu sol i jedan ili više drugih terapeutskih sredstava zajedno s uputama za davanje pacijentu u populaciji u kojoj su druge laktatne soli i jedan ili više drugih terapeutskih sredstava primenjena (ili se primenjuju); ili e = materijal koji sadrži najmanje jednu laktatnu sol i jedan ili više drugih terapeutskih sredstava u količini ili obliku koji je specifično prilagođen za uporabu u kombinaciji s drugim od dva ili više spojeva/sredstava.
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 5, naznačena time, da je aktivni spoj (c) odabran iz skupine koja se sastoji od (1) PDE IV inhibitora i (b) kortikosteroida.
a holder (3), which is connected to the base part (4) and to which an article is attachable; 
- - držač (3), koji je spojen na osnovni dio (4), na koji se predmet, poput znaka ili slično, priključuju, ili se namjerava priključiti;